November sees all rights granted to Biogen for Xbrane Biopharma’s XB003 proposed biosimilar to UCB’s Cimzia (certolizumab pegol) returned to the Swedish developer, as Xbrane gears up for another crucial month in its struggle to meet working capital requirements.
In August this year, Xbrane had stated that it must secure an out-licensing deal by October for either XB003...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?